Celgene Corporation (CELG) : Pictet Cie (europe) Sa scooped up 78,250 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 110,810 shares of Celgene Corporation which is valued at $12,564,746.Celgene Corporation makes up approximately 2.48% of Pictet Cie (europe) Sa’s portfolio.
Other Hedge Funds, Including , Cetera Investment Advisers reduced its stake in CELG by selling 260 shares or 3.13% in the most recent quarter. The Hedge Fund company now holds 8,040 shares of CELG which is valued at $911,656. Celgene Corporation makes up approx 0.35% of Cetera Investment Advisers’s portfolio.Isthmus Partners reduced its stake in CELG by selling 772 shares or 1.36% in the most recent quarter. The Hedge Fund company now holds 56,075 shares of CELG which is valued at $6,381,896. Celgene Corporation makes up approx 2.00% of Isthmus Partners’s portfolio.Tdam Usa boosted its stake in CELG in the latest quarter, The investment management firm added 3,414 additional shares and now holds a total of 30,182 shares of Celgene Corporation which is valued at $3,486,926. Celgene Corporation makes up approx 0.17% of Tdam Usa’s portfolio. Stanley-laman Group Ltd. added CELG to its portfolio by purchasing 9,108 company shares during the most recent quarter which is valued at $1,052,247. Celgene Corporation makes up approx 0.40% of Stanley-laman Group Ltd.’s portfolio.Nippon Life Insurance Co reduced its stake in CELG by selling 922 shares or 2.62% in the most recent quarter. The Hedge Fund company now holds 34,290 shares of CELG which is valued at $3,982,441. Celgene Corporation makes up approx 0.10% of Nippon Life Insurance Co’s portfolio.
Celgene Corporation opened for trading at $111.83 and hit $112.93 on the upside on Friday, eventually ending the session at $112.16, with a gain of 0.03% or 0.03 points. The heightened volatility saw the trading volume jump to 29,16,819 shares. Company has a market cap of $86,937 M.
On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.